uniQure (QURE) announced the presentation of a clinical case study of the first participant dosed in the first cohort of its ongoing Phase I/IIa trial of an investigational gene therapy candidate, AMT-260, in patients with refractory MTLE. The data are being presented today, May 29, 2025 by Firas Taha, M.D., Medical Director, Clinical Development at uniQure, at the Epilepsy Therapies & Diagnostics Development Symposium in Leesburg, Virginia.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Unusually active option classes on open May 21st
- uniQure’s Clinical and Regulatory Progress Drives Buy Rating Amid Market Overreaction
- Optimistic Buy Rating on uniQure Amidst Progress in Huntington’s Disease Program and AMT-130 Developments
- uniQure N.V. Earnings Call: Progress Amid Challenges
- uniQure Reports Q1 2025 Progress and Financials